This site is intended for health professionals only

Published on 1 May 2009

Share this story:

Kidney transplant drug tests well


A new drug designed to prevent organ rejection in kidney transplant patients has shown positive results in trials, it has been announced.

LCP-Tacro, from Denmark-based drug firm LifeCycle Pharma (LCP), can be safely and effectively administered once daily to kidney transplant patients, results from a recent study show.

The company’s research compared LCP-Tacro tablets administered once a day with Prograf capsules administered twice daily in 63 transplant patients.

The findings are further supported by preliminary six-month follow-up data into the randomised transplant patients after they have moved into the one-year maintenance stage of the study.

Dr Jim New, president and chief executive of LCP, said: “These results provide a very important milestone for LCP’s development activities in the transplantation therapeutic area. The unique potential benefits of LCP’s MeltDose formulation technology as applied to LCP-Tacro are clearly highlighted in the safety, efficacy, and controlled-release properties of this product.

“It’s also an important step forward for our transplantation franchise and our plan to commercialise LCP-Tacro within the US and European pharmaceutical markets.”

LCP has now launched a pivotal Phase III study into the treatment and will consult with the US Food and Drug Administration in order to submit a final Phase III protocol in the second half of 2009.

Copyright Press Association 2009

LifeCycle Pharma

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine